FDA delay takes bite out of Bristol Myers first mover advantage

22 November 2021
bristol_myers_large-1

A 2% share price drop followed Bristol Myers Squibb’s (NYSE: BMY) announcement on Friday that the US regulator is not yet ready to deliver a verdict on its submission for mavacamten.

The US Foo and Drug Administration has been reviewing data on the investigational drug, a first-in-class cardiac myosin inhibitor, as an option for people with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

The new deadline for a decision is April 28, 2022, with the extension allowing time to review “information pertaining to updates to the proposed Risk Evaluation Mitigation Strategy (REMS).”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical